Ian Anderson - Providence Med Grp, Santa Rosa, CA USA

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 18 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Trastuzumab Deruxtecan in Patients with Solid Tumours Harbouring Specific Activating HER2 Mutations (Destiny-Pantumor01): an International, Phase 2 Study

Bob T. Li,Funda Meric-Bernstam,Aditya Bardia,Yoichi Naito,Salvatore Siena,Philippe Aftimos,Ian Anderson,Giuseppe Curigliano,Maria de Miguel, Maitri Kalra,Do-Youn Oh,Joon Oh Park,Sophie Postel-Vinay,Sun Young Rha,Taroh Satoh,Iben Spanggaard,Flavia Michelini, Ann Smith, Karime Kalil Machado,Cristina Saura

LANCET ONCOLOGYno. 6 (2024): 707-719

引用0浏览0WOS引用

Lasofoxifene (LAS) Plus Abemaciclib (abema) for Treating ESR1-mutated ER+/HER2-metastatic Breast Cancer (mbc) after Progression on Prior Therapies: ELAINE 2 Study Update

Senthil Damodaran,Halle C. F. Moore,Ian Churchill Anderson,Mathew Amprayil Cherian,Ciara Catherine O'Sullivan,Paul V. Plourde,David Jay Portman,Matthew P. Goetz

Journal of clinical oncologyno. 16_suppl (2023): 1057-1057

引用3浏览0引用

Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach with a Just-in-TIME Model

Sibel Blau,Julio Antonio Peguero,Halle C. F. Moore,Ian Churchill Anderson,Minal A. Barve,Mathew Amprayil Cherian,Ahmed Elkhanany,Ciara Catherine O'Sullivan,Alvaro Moreno-Aspitia,Paul Plourde,Lyon L. Gleich,Kendra Riesen,Ross Ezzati,Meghan Degele,Megan Shulman, Stephanie Dobson Stempf,Laura Sachse,Amrita A. Iyer,Senthil Damodaran,Matthew M. Cooney

JCO CLINICAL CANCER INFORMATICS (2023)

引用0浏览0引用

Open-label, phase 2, multicenter study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre- and postmenopausal women with locally advanced or metastatic ER+/HER2-breast cancer and an ESR1 mutation after progression on prior therapies

Senthil Damodaran,Paul V. Plourde,Halle C. F. Moore,Ian Churchill Anderson,David Jay Portman

Journal of Clinical Oncologyno. 16 (2022): 1022-1022

引用13浏览0引用

SYST-06 INTRACRANIAL ACTIVITY OF TEPOTINIB IN PATIENTS WITH MET EXON 14 (METEX14) SKIPPING NSCLC ENROLLED IN VISION

Natasha Leighl,Christine Bestvina,Jyoti Patel,Xiuning Le,Remi Veillon,Ian Anderson,Ingel Demedts,Marina Chiara Garassino,Julien Mazières,Masahiro Morise,Egbert Smit,S Peter Eggleton,Aurora O’Brate,Gordon Otto,Rolf Bruns,Karl Maria Schumacher,Paul Paik

Neuro-oncology advancesno. Supplement_1 (2022): i22-i22

引用0浏览0引用

Intracranial Activity of Tepotinib in Patients (pts) with MET Exon 14 (metex14) Skipping NSCLC Enrolled in VISION

C. M. Bestvina,J. D. Patel,X. Le,R. Veillon,I. Anderson,I. Demedts,M. Garassino,J. Mazieres,M. Morise,E. Smit,S. P. Eggleton,A. O'Brate,G. Otto,R. Bruns,K. M. Schumacher,P. Paik

International Journal of Radiation OncologyBiologyPhysics（2022）

引用8浏览0引用

Open-label, phase 2, multicenter study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre- and postmenopausal women with locally advanced or metastatic ER+/HER2− breast cancer and an ESR1 mutation after progression on prior therapies

Senthil Damodaran,Paul V. Plourde,Halle C. F. Moore,Ian Churchill Anderson,David Jay Portman

Journal of Clinical Oncologyno. 16_suppl (2022): 1022-1022

引用0浏览0引用

Open-label, Phase II Study of Ladiratuzumab Vedotin (LV) for Castration-Resistant Prostate Cancer (SGNLVA-005, Trial-in-progress)

Amna Falak Sher,Justine Yang Bruce,Nashat Y. Gabrail,Ian Churchill Anderson,Anna Patrikidou,Rachel E. Sanborn,Jae Yong Cho,Arielle Shebay Lee, Jong-Seok Lee,Louise M. Nott,Do-Youn Oh,Sang Cheul Oh,Sung Yong Oh,Wang Yinghui,Wang Zejing,Troy H. Guthrie

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用1浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn